Identification of novel markers for 5-FU and FOLFOX toxicity.

about

Identification of novel markers for 5-FU and FOLFOX toxicity.

Item

http://www.wikidata.org/entity/Q49175955

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Identification of novel markers for 5-FU and FOLFOX toxicity.

@en

Identification of novel markers for 5-FU and FOLFOX toxicity.

@nl

type

Item

label

Identification of novel markers for 5-FU and FOLFOX toxicity.

@en

Identification of novel markers for 5-FU and FOLFOX toxicity.

@nl

prefLabel

Identification of novel markers for 5-FU and FOLFOX toxicity.

@en

Identification of novel markers for 5-FU and FOLFOX toxicity.

@nl

P1476

Identification of novel markers for 5-FU and FOLFOX toxicity.

@en

P2093

Sharon Marsh

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.

Pharmacogenomics--drug disposition, drug targets, and side effects.

Pharmacogenetics of colorectal cancer.

Ethnic differences in pharmacogenetically relevant genes.

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.

Genetic polymorphisms in the EGFR (R521K) and estrogen receptor (T594T) genes, EGFR and ErbB-2 protein expression, and breast cancer risk in Tunisia.

Cetuximab in the treatment of patients with colorectal cancer.

Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer.

Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.

Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.

P304

744-745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.12.42

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22594504

http://www.w3.org/2001/XMLSchema#string